Valuation : scPharmaceuticals Inc.

Market Cap 305M 262M 247M 225M 422M 28.8B 423M 2.92B 1.13B 14.76B 1.14B 1.12B 47.59B P/E 2027 *
-
P/E 2028 * -
Enterprise Value 281M 242M 227M 208M 388M 26.53B 390M 2.69B 1.04B 13.6B 1.05B 1.03B 43.85B EV / Sales 2027 *
-
EV / Sales 2028 * -
Free-Float
98.42%
Yield 2027 *
-
Yield 2028 * -
1 year 5.57
Extreme 5.57
5.7
3 years 1.94
Extreme 1.94
7.7
5 years 1.94
Extreme 1.94
12.75
10 years 1.94
Extreme 1.94
18.17
Manager TitleAgeSince
Chief Executive Officer 49 2025-10-06
Director of Finance/CFO 50 2025-10-06
Corporate Secretary 59 2025-10-06
Director TitleAgeSince
Director/Board Member 49 2025-10-06
Director/Board Member 59 2025-10-06
Director/Board Member 50 2025-10-06
Date Insider Type Main position Quantity % Market Cap. Importance
10/7/25 Issuer sale

Director

72,174 0.1442%
10/7/25 Issuer sale

Director

84,422 0.1687%
10/7/25 Issuer sale

Director

49,750 0.0994%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%+1.80%-19.00% 305M
-0.88%-2.15%+58.05%+105.26% 1,024B
-1.15%+2.68%+54.25%+74.19% 663B
-1.44%+0.38%+20.65%+76.13% 453B
+0.14%-0.47%+30.20%+41.44% 352B
-1.33%+4.72%+24.62%+48.58% 304B
-1.15%+0.30%-0.69%+13.20% 252B
-1.55%+1.11%+54.15%+75.59% 236B
-0.88%+1.15%-14.60%-54.96% 206B
-0.15%+3.65%+31.24%+103.39% 187B
Average -0.84%+0.98%+25.97%+46.38% 367.87B
Weighted average by Cap. -0.96%+0.55%+37.63%+68.01%

Financials

2027 *2028 *
Net sales - -
Net income - -
Net Debt - -
Logo scPharmaceuticals Inc.
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company’s strategy is to develop therapies for subcutaneous administration that have previously been limited to intravenous (IV) delivery. Its commercial product, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Company’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Employees
163
  1. Stock Market
  2. Stocks
  3. SCPH Stock